Individuals who suffer from symptoms of gastrointestinal, autoimmune, dermatological and pain conditions make up 80% of the patient population. But here’s the good news: multiple studies indicate that low-dose naltrexone (LDN) may potentially help many of these conditions. Take a sneak peek at topics our Clinical Services team will discuss during the Low-Dose Naltrexone One-Day Virtual Conference on Thursday, November 21, 2024.

Perimenopause is a unique phase in a woman’s life, marked by fluctuating hormones and a wide range of symptoms. Hormone replacement therapy (HRT) can offer relief, but a one-size-fits-all approach may not yield the best results. A personalized approach, tailored to each woman’s unique hormonal profile, lifestyle and symptoms, can make all the difference in managing this transition effectively. Let’s explore the factors that contribute to low estrogen, the role of cortisol and progesterone, and why a customized approach to HRT is essential for perimenopausal women.

At PCCA Science, we continuously build and grow scientific support for compounding and the technologies our members use in their practices. We test our bases using various methods before, during and after the release of a new product. We regularly submit results of these studies for publication in peer-reviewed journals and make them available to our members, who in turn can share them with prescribers, physicians and patients.

Since 2014, there’s been an explosion of information about the potential applications of low-dose naltrexone (LDN), including use as an adjunct therapeutic in some types of cancer. The exploration of LDN in cancer treatment underscores the importance of understanding the complex interplay between immune signaling and cancer biology, which we discuss in the following article.

ThinkNext: International Seminar 2024 (ThinkNext: ISTX24), held October 17 - 19 in Houston, Texas, was a huge success with well over 500 rockstar compounders from around the world. We’re sharing seminar highlights and memorable takeaways that make PCCA members return year after year.

October 15 is National Pharmacy Technician Day! Our Profile in Personalize Medicine highlights Katie Albers, CPhT, Pharmacy Manager and Co-Owner, along with Dawn Trame, RPh, and Richard W. Schulte, Esq., of Impact Compounding, located in Tipp City, Ohio. We asked Katie what “Compounding: It’s Personal” means to her and her pharmacy, why she was drawn to compounding and so much more.

Thyroid health plays a pivotal role in regulating metabolism, energy levels and overall well-being.1 Among the spectrum of thyroid disorders, subclinical hypothyroidism often flies under the radar due to its subtle symptoms. However, its implications on weight management warrants closer attention. Taking a closer look into what subclinical hypothyroidism entails, its connection to weight loss challenges, the importance of appropriate testing, and how excipients in medications can influence thyroid hormone absorption can help many patients with this elusive condition.

The United States Pharmacopeia (USP) General Chapter 800 addresses the handling of hazardous drugs (HDs) to minimize the risk of exposure to patients, health care workers and the environment. It became compendially applicable in November 2023. USP 800 contains some key elements that specifically apply to employee safety and HD containment. Section 16, for example, discusses managing HD spills and retaining spill kits on site. This article addresses HD spills that occur in a compounding pharmacy; however, it can be adapted for handling of non-HD chemical spills as well.

In the race to unlock the secrets of longevity, one of the most exciting areas of research is mitochondrial health. These tiny organelles, often referred to as the "powerhouses" of the cell, are responsible for producing the energy (ATP) that fuels every cell in the body. As we age, mitochondrial function tends to decline, leading to reduced energy, increased oxidative stress and accelerated aging. Maximizing mitochondrial health has emerged as a key strategy for extending both lifespan and health span — how long we live and how well we live.1

Our Profiles in Personalized Medicine highlights Erik Nelson, PharmD, FAAMFM, FACA, owner of Koru Pharmacy in Spokane, Washington. Erik shares what “Compounding: It’s Personal” means in his pharmacy, his motivation to become a compounding pharmacist, a special patient success story and more. Erik has been a proud PCCA member since 2013.